Pioneering sustainable treatment delivery in childhood leukemia through synchronous telemedicine—A pilot study

Andreas Meryk,Christina Salvador,Gabriele Kropshofer,Benjamin Hetzer,Gerhard Rumpold,Alexandra Haid,Verena Schneeberger‐Carta,Bernhard Holzner,Roman Crazzolara
DOI: https://doi.org/10.1002/ijc.35253
2024-11-11
International Journal of Cancer
Abstract:What's New? Cancer care requires frequent traveling to centralized health care services, placing an additional burden on patients from rural areas. This prospective study aimed to implement a telemedicine‐based integrated health care network for maintenance treatment in acute childhood leukemia. The network provided outpatient services imparted by local physicians and synchronous telemedicine consultations with pediatric oncologists. The findings demonstrate that a telemedicine‐based integrated health care network can be implemented in the routine clinical care of pediatric leukemia patients and may ensure quality of care, reduced travel costs, safety, and satisfaction from both families and clinicians. Cancer care places a heavy economic burden on families and health systems, driven by high treatment costs, lengthy hospital stays, and the necessity for extensive travel to specialized facilities. To address this challenge, an integrated health care network (IHCN) was implemented for maintenance treatment in acute leukemia. The IHCN encompassed outpatient services provided by local physicians and synchronous telemedicine consultation with pediatric oncologists. This study included twenty‐two pediatric patients (eleven [50.0%] females; twenty [90.9%] with B‐ALL and two [9.1%] with AML). The IHCN was offered to all rural patients (n = 17) with a one‐way driving distance more than 30 km, while urban patients (n = 5) received regular cancer care. Throughout the study, rural patients had a total of 510 routine clinical visits, with 367 (72%) conducted through the IHCN. Physical examinations revealed similar frequency of new abnormal findings for urban and rural patients (22.4% vs. 17.8%; p = .31). Laboratory tests indicated no significant difference in the frequency of abnormal values for various parameters between both groups. Similarly, there was no discrepancy of drug modifications or interruption in maintenance therapy between the two settings (p = .85). Moreover, patients' health‐related quality of life remained within the normative range, and user satisfaction with the IHCN was notably high. The implementation of the IHCN resulted in savings of 70,158 km, 950 h of travel, and 12,277 kg CO2 emissions. This pilot study underscores the efficacy of a telemedicine‐based IHCN, ensuring safety, quality of care, cost reduction, and satisfaction for both families and health care providers in pediatric leukemia management.
oncology
What problem does this paper attempt to address?